AmerisourceBergen extends $2.4 billion revolver to 2027

By Wendy Van Sickle

Columbus, Ohio, Oct. 27 – AmerisourceBergen Corp. and its subsidiaries BP Pharmaceuticals Laboratories Unlimited Co., Centaur Services Ltd. and Innomar Strategies Inc. amended and restated their $2.4 billion multicurrency revolving credit facility on Oct. 27, extending the maturity date to Oct. 27, 2027, according to an 8-K filing with the Securities and Exchange Commission.

Certain changes were also made to effect a transitioning of the interest benchmark to SOFR from Libor.

Interest now accrues at SOFR plus a margin ranging from 80.5 basis points to 122.5 bps, depending on ratings of the company.

The commitment fee ranges from 7 bps to 15 bps and is also based on ratings.

There is a $75 million sublimit for letters of credit.

JPMorgan Chase Bank, NA, BofA Securities, Inc., Citibank, NA and Wells Fargo Securities LLC are the lead arrangers and joint bookrunners with JPMorgan as administrative agent, Bank of America, NA, Citibank and Wells Fargo Bank NA as syndication agents and Morgan Stanley Senior Funding, Inc., MUFG Bank Ltd., Bank of Nova Scotia and U.S. Bank NA as documentation agents.

The revolving credit agreement is originally dated March 18, 2011.

Proceeds of the revolver may be used for general corporate purposes.

Based in Chesterbrook, Pa., AmerisourceBergen provides drug distribution and related services to pharmaceutical manufacturers in the United States and Canada.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.